Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran


The preoperative care of patients undergoing orthopedic surgery and treated with biologic agents is of great significance.
Perioperative use of biologic agents could lead to such complications as infection and delayed postoperative wound
healing. This narrative review aimed to evaluate the current information on the use of biologic agents in patients
undergoing orthopedic surgery, determine the rate of associated postoperative complications, and identify the
appropriate time for the continuation or discontinuation of biologic therapy in these patients. It can be stated that
all biologic agents increase the risk of infections depending on their half-lives. Biologic agents are suggested to be
withheld for at least twice their half-lives before major surgeries. However, in case of minor operations, they can be
continued given the low risk of infection and impaired wound healing in these cases.
Level of evidence: I


Main Subjects

1. Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin
X, Peyrin-Biroulet L. Preoperative use of anti-
TNF therapy and postoperative complications in
inflammatory bowel diseases: a meta-analysis. J
Crohn’s Colitis. 2013; 7(11):853-67.
2. Krause ML, Matteson EL. Perioperative management
of the patient with rheumatoid arthritis. World J
Orthop. 2014; 5(3):283-91.
3. Bongartz T. Elective orthopedic surgery and
perioperative DMARD management: many questions,
fewer answers, and some opinions. J Rheumatol.
2007; 34(4):653-5.
4. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-
TNF therapy be discontinued in rheumatoid arthritis
patients undergoing elective orthopaedic surgery?
A systematic review of the evidence. Rheumatol Int.
2012; 32(1):5-13.
5. Akkara Veetil BM, Bongartz T. Perioperative care for
patients with rheumatic diseases. Nat Rev Rheumatol.
2012; 8(1):32-41.

6. Johnson BK, Goodman SM, Alexiades MM, Figgie MP,
Demmer RT, Mandl LA. Patterns and associated risk
of perioperative use of anti-tumor necrosis factor in
patients with rheumatoid arthritis undergoing total
knee replacement. J Rheumatol. 2013; 40(5):617-23.
7. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel
SE. Frequency of infection in patients with rheumatoid
arthritis compared with controls: a population‐based
study. Arthritis Rheum. 2002; 46(9):2287-93.
8. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y,
Hobo K. Clinical factors related to the efficacy and
complications of orthopedic surgery for rheumatoid
arthritis with infliximab. Int J Rheum Dis. 2011;
9. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramersde
Quervain IA. Infection risk after orthopedic surgery
in patients with inflammatory rheumatic diseases
treated with immunosuppressive drugs. Arthritis
Care Res. 2013; 65(12):2032-40.
10. den Broeder AA, Creemers MC, Fransen J, de Jong E,
de Rooij DJ, Wymenga A, et al. Risk factors for surgical
site infections and other complications in elective
surgery in patients with rheumatoid arthritis with
special attention for anti-tumor necrosis factor: a large
retrospective study. J Rheumatol. 2007; 34(4):689-95.
11. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J,
Balint G, et al. Double‐blind randomized controlled
clinical trial of the interleukin‐6 receptor antagonist,
tocilizumab, in European patients with rheumatoid
arthritis who had an incomplete response to
methotrexate. Arthritis Rheum. 2006; 54(9):2817-29.
12. Talwalkar S, Grennan D, Gray J, Johnson P, Hayton
M. Tumour necrosis factor α antagonists and early
postoperative complications in patients with
inflammatory joint disease undergoing elective
orthopaedic surgery. Ann Rheum Dis. 2005;
13. Wendling D, Balblanc JC, Brousse A, Lohse A, Lehuede
G, Garbuio P, et al. Surgery in patients receiving antitumour
necrosis factor α treatment in rheumatoid
arthritis: an observational study on 50 surgical
procedures. Ann Rheum Dis. 2005; 64(9):1378-9.
14. Corrao S, Pistone G, Arnone S, Calvo L, Scaglione R,
Licata G. Safety of etanercept therapy in rheumatoid
patients undergoing surgery: preliminary report. Clin
Rheumatol. 2007; 26(9):1513-5.
15. Bibbo C, Goldberg JW. Infectious and healing
complications after elective orthopaedic foot and
ankle surgery during tumor necrosis factor-alpha
inhibition therapy. Foot Ankle Int. 2004; 25(5):331-5.
16. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi
M, Kida D, et al. Influences of anti-tumour necrosis
factor agents on postoperative recovery in patients
with rheumatoid arthritis. Clin Rheumatol. 2010;
17. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos
M, Guignard S, et al. Complication rates of 127
surgical procedures performed in rheumatic patients
receiving tumor necrosis factor alpha blockers. Clin
Exp Rheumatol. 2007; 25(3):430-6.
18. Kawakami K, Ikari K, Kawamura K, Tsukahara S,
Iwamoto T, Yano K, et al. Complications and features
after joint surgery in rheumatoid arthritis patients
treated with tumour necrosis factor-α blockers:
perioperative interruption of tumour necrosis factor-α
blockers decreases complications? Rheumatol. 2010;
19. Momohara S, Kawakami K, Iwamoto T, Yano K,
Sakuma Y, Hiroshima R, et al. Prosthetic joint infection
after total hip or knee arthroplasty in rheumatoid
arthritis patients treated with nonbiologic and
biologic disease-modifying antirheumatic drugs. Mod
Rheumatol. 2011; 21(5):469-75.
20. Bongartz T, Halligan CS, Osmon DR, Reinalda MS,
Bamlet WR, Crowson CS, et al. Incidence and risk
factors of prosthetic joint infection after total hip
or knee replacement in patients with rheumatoid
arthritis. Arthritis Rheum. 2008; 59(12):1713-20.
21. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine
K, Ruffing V, et al. Tumor necrosis factor inhibitor
therapy and risk of serious postoperative orthopedic
infection in rheumatoid arthritis. Arthritis Rheum.
2006; 55(2):333-7.
22. Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M,
Suguro T. Perioperative complications in elective
surgery in patients with rheumatoid arthritis treated
with biologics. Mod Rheumatol. 2012; 22(6):844-8.
23. Galloway J, Hyrich K, Mercer L, Dixon W, Ustianowski
A, Helbert M, et al. Risk of septic arthritis in patients
with rheumatoid arthritis and the effect of anti-
TNF therapy: results from the British Society for
Rheumatology Biologics Register. Ann Rheum Dis.
2011; 70(10):1810-4.
24. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot
MH, Berthelot JM, et al. Risk factors for total joint
arthroplasty infection in patients receiving tumor
necrosis factor α-blockers: a case-control study.
Arthritis Res Ther. 2010; 12(4):R145.
25. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA,
Wagner DD. Antithrombotic activity of TNF-α. J Clin
Invest. 2003; 112(10):1589-96.
26. Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth
TG, Alten R, Pohl C, et al. Identifying core domains
to assess flare in rheumatoid arthritis: an OMERACT
international patient and provider combined Delphi
consensus. Ann Rheum Dis. 2012; 71(11):1855-60.
27. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD,
Strand V, et al. High disease activity is associated
with an increased risk of infection in patients
with rheumatoid arthritis. Ann Rheum Dis. 2011;
28. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C,
Curtis JR, et al. American College of Rheumatology
2008 recommendations for the use of nonbiologic
and biologic disease‐modifying antirheumatic drugs
in rheumatoid arthritis. Arthritis Rheum. 2008;
29. Ding T, Ledingham J, Luqmani R, Westlake S,
Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid
arthritis guidelines on safety of anti-TNF therapies.
Rheumatology (Oxford). 2010; 49(11):2217-9.
30. voor Reumatologie NV. Medicijnen: het toepassen van

TNF-Blokkade in de behandeling van Reumatoï􀇅de
Artritis. Utrecht: Dutch Society for Rheumatology;
31. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille
P, Hilliquin P, et al. Anti-TNF alpha therapy and safety
monitoring. Clinical tool guide elaborated by the Club
Rhumatismes et Inflammations (CRI), section of the
French Society of Rheumatology (Societe Francaise de
Rhumatologie, SFR). Joint Bone Spine. 2005; 72(Suppl
32. Nestorov I. Clinical pharmacokinetics of TNF
antagonists: how do they differ? Semin Arthritis
Rheum. 2005; 34(5 Suppl 1):12-8.
33. Ledingham J, Deighton C. Update on the British Society
for Rheumatology guidelines for prescribing TNFα
blockers in adults with rheumatoid arthritis (update
of previous guidelines of April 2001). Rheumatology
(Oxford). 2005; 44(2):157-63.
34. Bombardier C, Hazlewood GS, Akhavan P, Schieir O,
Dooley A, Haraoui B, et al. Canadian Rheumatology
Association recommendations for the pharmacological
management of rheumatoid arthritis with traditional
and biologic disease-modifying antirheumatic drugs:
part II safety. J Rheumatol. 2012; 39(8):1583-602.
35. Koike R, Takeuchi T, Eguchi K, Miyasaka N. Update on
the Japanese guidelines for the use of infliximab and
etanercept in rheumatoid arthritis. Mod Rheumatol.
2007; 17(6):451-8.
36. Woodward L, Kam P. Ankylosing spondylitis:
recent developments and anaesthetic implications.
Anaesthesia. 2009; 64(5):540-8.
37. Baraliakos X, Braun J. Anti-TNF-α therapy with
infliximab in spondyloarthritides. Expert Rev Clin
Immunol. 2010; 6(1):9-19.
38. White CA, Weaver RL, Grillo-López AJ. Antibodytargeted
immunotherapy for treatment of malignancy.
Ann Rev Med. 2001; 52(1):125-45.
39. Buch MH, Smolen JS, Betteridge N, Breedveld FC,
Burmester G, Dörner T, et al. Updated consensus
statement on the use of rituximab in patients
with rheumatoid arthritis. Ann Rheum Dis. 2011;
40. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein
MR, Salden M, Bodman‐Smith M, et al. Serologic
changes following B lymphocyte depletion therapy
for rheumatoid arthritis. Arthritis Rheum. 2003;
41. Godot S, Gottenberg JE, Paternotte S, Pane I, Combe
B, Sibilia J, et al. Safety of surgery after rituximab
therapy in 133 patients with rheumatoid arthritis:
data from the autoimmunity and rituximab registry.
Arthritis Care Res. 2013; 65(11):1874-9.
42. Saech J, Maizus K, Owczarczyk K, Roehrs T, Benenson
E, Rubbert A. Rituximab in patients with rheumatoid
arthritis and surgical intervention. Ann Rheum Dis.
2009; 68(Suppl 3):S443.
43. Sibilia J, Gottenberg JE, Mariette X. Rituximab: a new
therapeutic alternative in rheumatoid arthritis. Joint
Bone Spine. 2008; 75(5):526-32.
44. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci
C, Sica G, et al. B cells in systemic sclerosis: a
possible target for therapy. Autoimmun Rev. 2011;
45. Goodman SM, Paget S. Perioperative drug safety in
patients with rheumatoid arthritis. Rheum Dis Clin
North Am. 2012; 38(4):747-59.
46. Scanzello CR, Figgie MP, Nestor BJ, Goodman SM.
Perioperative management of medications used in
the treatment of rheumatoid arthritis. HSS J. 2006;
47. Maxwell LJ, Singh JA. Abatacept for rheumatoid
arthritis: a Cochrane systematic review. J Rheumatol.
2010; 37(2):234-45.
48. Pham T, Claudepierre P, Constantin A, Fautrel B,
Gossec L, Gottenberg JE, et al. Abatacept therapy and
safety management. Joint Bone Spine. 2009; 76(Suppl
49. Bissar L, Almoallim H, Albazli K, Alotaibi M, Alwafi S.
Perioperative management of patients with rheumatic
diseases. Open Rheumatol J. 2013; 7(1):42-50.
50. Nishida K, Nasu Y, Hashizume K, Nakahara R, Ozawa
M, Harada R, et al. Abatacept management during
the perioperative period in patients with rheumatoid
arthritis: report on eight orthopaedic procedures.
Mod Rheumatol. 2014; 24(3):544-5.
51. Latourte A, Gottenberg JE, Luxembourger C, Pane
I, Claudepierre P, Richette P, et al. Safety of surgery
in patients with rheumatoid arthritis treated
by abatacept: data from the French Orencia in
Rheumatoid Arthritis Registry. Rheumatology
(Oxford). 2017; 56(4):629-37.
52. Salliot C, Dougados M, Gossec L. Risk of serious
infections during rituximab, abatacept and anakinra
treatments for rheumatoid arthritis: meta-analyses
of randomised placebo-controlled trials. Ann Rheum
Dis. 2009; 68(1):25-32.
53. Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A,
Combe B, Flipo RM, et al. Predictive risk factors
of serious infections in patients with rheumatoid
arthritis treated with abatacept in common practice:
results from the Orencia and Rheumatoid Arthritis
(ORA) registry. Ann Rheum Dis. 2016; 75(6):1108-13.
54. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP,
Soma K, et al. Safety and efficacy of tofacitinib, an oral
janus kinase inhibitor, for the treatment of rheumatoid
arthritis in open-label, longterm extension studies. J
Rheumatol. 2014; 41(5):837-52.